Shattered dream of sickle cell disease cure to end in reverse merger for Peninsula biotech

Even before its gene-editing therapy reached (and failed in) a clinical trial, the company executed a $274 million IPO during the Covid-19 biotech boom.

Previous HCA Healthcare CEO Sam Hazen to moderate 2024 Nashville Health Care Council event
Next Gwinnett population boom fuels health care expansion